The biotech world was abuzz Sunday, after the Mail on Sunday in London reported that Japan-based Takeda Pharmaceuticals was looking at acquiring Cambridge-based Genzyme Corp. It’s not that far-fetched. After all, Takeda, like many other big pharmas, is looking to refill its drug pipeline, especially as its best-selling diabetes drug, Actos, will go off patent in the U.S. in January, opening the drug up to generic competition here. The company is also quite comfortable in Cambridge, having purchased Genzyme’s neighbor, Millennium Pharmaceuticals, in 2008 for about $9 billion.
Genzyme, busily defending itself against the $69 per share hostile takeover bid from French pharma Sanofi-aventis, which expires on Dec. 3, is looking for a price somewhere around $80 and has said it is open to other offers. Takeda could pay $82 a share for the company, the British newspaper reported, citing an unnamed source.